106
Z. Liu and Y. Liu
agents, carrier materials or recognition molecules. Strategies for drug and aptamer
conjugation have been extended and environment responsive linkers are designed and
used for drugs loading and release. The chemical flexibility of aptamer provides huge
potential for functionalization of nanoparticles. The aptamers have versatility and
therapeutic applications. However, the clinical transformation of aptamer-based drug
delivery systems is still a big challenge at the moment. Moreover, the optimization
of bioconjugation as well as their applicability and toxicological aspects still need
to be further investigated. In addition, large-scale production technology and costs
should also be taken into consideration.
Acknowledgements This work was financially supported by the Huxiang Young Talent Support
Program of Hunan Province (2018RS3005), the Innovation-Driven Project of Central South University (2020CX048), the National Natural Science Foundation of China (81301258), the Changsha
Science and Technology Plan Project (kq2005001, kq2004086), the Natural Science Foundation
of Hunan Province (2019JJ60071, 2020JJ4680), the Shenghua Yuying Project of Central South
University, the Open-End Fund for the Valuable and Precision Instruments of Central South
University.
References
1. Ashley EA (2016) Towards precision medicine. Nat Rev Genet 17(9):507–522
2. Zhu G, Chen X (2018) Aptamer-based targeted therapy. Adv Drug Deliv Rev 134:65–78
3. Srinivasarao M, Galliford CV, Low PS (2015) Principles in the design of ligand-targeted
cancer therapeutics and imaging agents. Nat Rev Drug Discov 14(3):203–219
4. Xiong H, Yan J, Cai S, He Q, Peng D, Liu Z, Liu Y (2019) Cancer protein biomarker discovery
based on nucleic acid aptamers. Int J Biol Macromol 132:190–202
5. Cai S, Yan J, Xiong H, Liu Y, Peng D, Liu Z (2018) Investigations on the interface of nucleic
acid aptamers and binding targets. Analyst 143(22):5317–5338
6. Zhou J, Rossi J (2017) Aptamers as targeted therapeutics: current potential and challenges.
Nat Rev Drug Discov 16(3):181–202
7. Liu Z, Shi Y, Chen Z, Duan L, Wang X (2014) Current progress towards the use of aptamers
in targeted cancer therapy. Chin Sci Bull 14:1267–1279
8. He F, Wen N, Xiao D, Yan J, Xiong H, Cai S, Liu Z, Liu Y (2020) Aptamer based targeted
drug delivery systems: current potential and challenges. Curr Med Chem 27(13):2189–2219
9. Takahashi M (2018) Aptamers targeting cell surface proteins. Biochimie 145:63–72
10. Yan J, Xiong H, Cai S, Wen N, He Q, Liu Y, Peng D, Liu Z (2019) Advances in aptamer
screening technologies. Talanta 200:124–144
11. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W (2011) RNA aptamer against a cancer
stem cell marker epithelial cell adhesion molecule. Cancer Sci 102(5):991–998
12. Zhu G, Zhang H, Jacobson O, Wang Z, Chen H, Yang X, Niu G, Chen X (2017) Combinatorial
screening of DNA aptamers for molecular Imaging of HER2 in cancer. Bioconjug Chem
28(4):1068–1075
13. Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD (2012) Novel MUC1 aptamer selectively
delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 7(2):e31970
14. Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nucleasestabilized RNA molecules that bind human prostate cancer cells via the prostate-specific
membrane antigen. Cancer Res 62(14):4029–4033
Z. Liu and Y. Liu
agents, carrier materials or recognition molecules. Strategies for drug and aptamer
conjugation have been extended and environment responsive linkers are designed and
used for drugs loading and release. The chemical flexibility of aptamer provides huge
potential for functionalization of nanoparticles. The aptamers have versatility and
therapeutic applications. However, the clinical transformation of aptamer-based drug
delivery systems is still a big challenge at the moment. Moreover, the optimization
of bioconjugation as well as their applicability and toxicological aspects still need
to be further investigated. In addition, large-scale production technology and costs
should also be taken into consideration.
Acknowledgements This work was financially supported by the Huxiang Young Talent Support
Program of Hunan Province (2018RS3005), the Innovation-Driven Project of Central South University (2020CX048), the National Natural Science Foundation of China (81301258), the Changsha
Science and Technology Plan Project (kq2005001, kq2004086), the Natural Science Foundation
of Hunan Province (2019JJ60071, 2020JJ4680), the Shenghua Yuying Project of Central South
University, the Open-End Fund for the Valuable and Precision Instruments of Central South
University.
References
1. Ashley EA (2016) Towards precision medicine. Nat Rev Genet 17(9):507–522
2. Zhu G, Chen X (2018) Aptamer-based targeted therapy. Adv Drug Deliv Rev 134:65–78
3. Srinivasarao M, Galliford CV, Low PS (2015) Principles in the design of ligand-targeted
cancer therapeutics and imaging agents. Nat Rev Drug Discov 14(3):203–219
4. Xiong H, Yan J, Cai S, He Q, Peng D, Liu Z, Liu Y (2019) Cancer protein biomarker discovery
based on nucleic acid aptamers. Int J Biol Macromol 132:190–202
5. Cai S, Yan J, Xiong H, Liu Y, Peng D, Liu Z (2018) Investigations on the interface of nucleic
acid aptamers and binding targets. Analyst 143(22):5317–5338
6. Zhou J, Rossi J (2017) Aptamers as targeted therapeutics: current potential and challenges.
Nat Rev Drug Discov 16(3):181–202
7. Liu Z, Shi Y, Chen Z, Duan L, Wang X (2014) Current progress towards the use of aptamers
in targeted cancer therapy. Chin Sci Bull 14:1267–1279
8. He F, Wen N, Xiao D, Yan J, Xiong H, Cai S, Liu Z, Liu Y (2020) Aptamer based targeted
drug delivery systems: current potential and challenges. Curr Med Chem 27(13):2189–2219
9. Takahashi M (2018) Aptamers targeting cell surface proteins. Biochimie 145:63–72
10. Yan J, Xiong H, Cai S, Wen N, He Q, Liu Y, Peng D, Liu Z (2019) Advances in aptamer
screening technologies. Talanta 200:124–144
11. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W (2011) RNA aptamer against a cancer
stem cell marker epithelial cell adhesion molecule. Cancer Sci 102(5):991–998
12. Zhu G, Zhang H, Jacobson O, Wang Z, Chen H, Yang X, Niu G, Chen X (2017) Combinatorial
screening of DNA aptamers for molecular Imaging of HER2 in cancer. Bioconjug Chem
28(4):1068–1075
13. Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD (2012) Novel MUC1 aptamer selectively
delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 7(2):e31970
14. Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nucleasestabilized RNA molecules that bind human prostate cancer cells via the prostate-specific
membrane antigen. Cancer Res 62(14):4029–4033